Significant reduction in end-stage liver diseases burden through the national viral hepatitis therapy program in Taiwan

Hepatology

Volumn 61, Issue 4, 2015, Pages 1154-1162

  Chiang, Chun Ju ^a,b   Yang, Ya Wen ^a,b   Chen, Jin De ^c   You, San Lin ^b,d,e   Yang, Hwai I ^d   Lee, Mei Hsuan ^f   Lai, Mei Shu ^a,b   Chen, Chien Jen ^a,b,d  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b Taiwan Cancer Registry   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d GENOMICS RESEARCH CENTER   (Taiwan)

^e FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^f NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; CANCER RISK; CHRONIC HEPATITIS; CHRONIC LIVER DISEASE; DECOMPENSATED LIVER CIRRHOSIS; END STAGE LIVER DISEASE; FEMALE; HEALTH PROGRAM; HEPATITIS B; HEPATITIS C; HUMAN; INCIDENCE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; NATIONAL VIRAL HEPATITIS THERAPY PROGRAM; PRIORITY JOURNAL; PROGRAM EFFECTIVENESS; REIMBURSEMENT; TAIWAN; CARCINOMA, HEPATOCELLULAR; COMPLICATION; COST OF ILLNESS; HEPATITIS, VIRAL, HUMAN; LIVER NEOPLASMS; MIDDLE AGED; PUBLIC HEALTH;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; COST OF ILLNESS; END STAGE LIVER DISEASE; HEPATITIS, VIRAL, HUMAN; HUMANS; INCIDENCE; LIVER CIRRHOSIS; LIVER NEOPLASMS; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; TAIWAN;

EID: 84925348775     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27630     Document Type: Article

References (37)

1. Chen DS. Hepatocellular carcinoma in Taiwan. Hepatol Res 2007;37:S101-S105.
2. Centers for Disease Control, Department of Health, Taiwan, ROC. Annual report 2012. http://www.cdc.gov.tw/uploads/files/201208/67addf76-0493-4d7b-aa72-cd51beff6654.pdf. Accessed February 17, 2013.
3. Chen CJ, Yang HI. Natural history of chronic hepatitis B REVEALed. J Gastroenterol Hepatol 2011;26:628-638.
4. Huang YT, Jen CL, Yang HI, Lee MH, Su J, Lu SN, et al. Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C. J Clin Oncol 2011;29:3643-3650.
5. Chen DS, Hsu NH, Sung JL, Hsu TC, Hsu ST, Kuo YT, et al. A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B carrier-mothers. JAMA 1987;257:2597-2603.
6. Chien YC, Jan CF, Kuo HS, Chen CJ. Nationwide hepatitis B vaccination program in Taiwan: effectiveness in the 20 years after it was launched. Epidemiol Rev 2006;28:126-135.
7. Chiang CJ, Yang YW, You SL, Lai MS, Chen CJ. Thirty-year outcomes of the national hepatitis B immunization program in Taiwan. JAMA 2013;310:974-976.
8. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-1531.
9. Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, et al. Long-term entecavir therapy results in reversal of fibrosis/cirrhosis and continued histologic improvement in chronic hepatitis B patients. Hepatology 2010;52:886-893.
10. Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol 2010;53:348-356.
11. Liaw YF. Reversal of cirrhosis: an achievable goal of hepatitis B antiviral therapy. J Hepatol 2013;59:880-881.
12. Camma C, Giunta M, Andreone P, Craxì A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol 2001;34:593-602.
13. Shiratori Y, Ito Y, Yokosuka O, Imazeki F, Nakata R, Tanaka N, et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 2005;142:105-114.
14. Ministry of Health and Welfare, Taiwan, ROC. Taiwan Public Health Report 2012. http://www.mohw.gov.tw/EN/Ministry/DM2_P.aspx?f_list_no=475&fod_list_no=853&doc_no=29943. Accessed August 16, 2013.
15. Chang CH, Liu JW, Wu LC, Liu C, Lai MS. National antiviral treatment program and the incidence of hepatocellular carcinoma and association mortality in Taiwan: a preliminary report. Med Care 2013;51:908-913.
16. Wen CP, Tsai SP, Chung WS. A 10-year experience with universal health insurance in Taiwan: measuring changes in health and health disparity. Ann Intern Med 2008;148:258-267.
17. Chen CF, Lee WC, Yang HI, Chang HC, Jen CL, Iloeje UH, et al. Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma. Gastroenterology 2011;141:1240-1248.
18. Lee MH, Yang HI, Lu SN, Jen CL, Yeh SH, Liu CJ, et al. Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma: long-term predictors from a community-based cohort study. J Clin Oncol 2010;28:4587-4593.
19. Chiang CJ, Chen YC, Chen CJ, You SL, Lai MS, Taiwan Cancer Registry Task Force. Cancer trends in Taiwan. Jpn J Clin Oncol 2010;40:897-904.
20. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002;347:168-174.
21. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73.
22. Iloeje UH, Yang HI, Jen CL, Jen CL, You SL, Chen CJ, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130:678-686.
23. Liaw YF. Antiviral therapy of chronic hepatitis B: opportunities and challenges in Asia. J Hepatol 2009;51:403-410.
24. Lee MH, Yang HI, Lu SN, Wang JH, Lee CM, Chen CH, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis 2012;206:469-477.
25. Peng CY, Chien RN, Liaw YF. Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy. J Hepatol 2012;57:442-450.
26. Wu CY, Lin JT, Ho HJ, Su CW, Lee TY, Wang SY, et al. Association of nucleostide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B-a nationwide cohort study. Gastroenterology 2014;147:143-151.
27. Yu ML, Chuang WL. Treatment of chronic hepatitis C in Asia: when East meets West. J Gastroenterol Hepatol 2009;24:336-345.
28. Hsieh CR, Kuo CW. Cost of chronic hepatitis B virus infection in Taiwan. J Clin Gastroenterol 2004;38:S148-S152.
29. Wong JB. Hepatitis C: cost of illness and considerations for the economic evaluation of antiviral therapies. Pharmacoeconomics 2006;24:661-672.
30. Wu CY, Chen YJ, Ho HJ, Hsu YC, Kuo KN, Wu MS, et al. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA 2012;308:1906-1913.
31. Lu SN, Su WW, Yang SS, Chang TT, Cheng KS, Wu JC, et al. Secular trends and geographic variations of hepatitis B virus and hepatitis C virus-associated hepatocellular carcinoma in Taiwan. Int J Cancer 2006;119:1946-1952.
32. Lai MY, Kao JH, Yang PM, Wang JT, Chen PJ, Chan KW, et al. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology 1996;111:1307-1312.
33. Kee KM, Lu SN. Hospital- and community-based screenings for hepatocellular carcinoma in Taiwan. Oncology 2011;81(Suppl 1):36-40.
34. Chen CH, Su WW, Yang SS, Chang TT, Cheng KS, Lin HH, et al. Long-term trends and geographic variations in the survival of patients with hepatocellular carcinoma: analysis of 11, 312 patients in Taiwan. J Gastroenterol Hepatol 2006;21:1561-1566.
35. Kuo YH, Lu SN, Chen CL, Cheng YF, Lin CY, Hung CH, et al. Hepatocellular carcinoma surveillance and appropriate treatment options improve survival for patients with liver cirrhosis. Eur J Cancer 2010;46:744-751.
36. Ministry of Health and Welfare, Taiwan, ROC. Statistics of causes of death 2012. http://www.mohw.gov.tw/EN/Ministry/DM2.aspx?f_list_no=474&fod_list_no=3523. Accessed July 18, 2013.
37. Wait S, Chen DS. Towards the eradication of hepatitis B in Taiwan. Kaohsiung J Med Sci 2012;28:1-9.